|
gptkbp:instanceOf
|
gptkb:Hallucinogen
gptkb:alkaloid
|
|
gptkbp:biosynthesized_from
|
tryptophan
|
|
gptkbp:boilingPoint
|
160–180 °C (decomposes)
|
|
gptkbp:CASNumber
|
61-50-7
|
|
gptkbp:category
|
gptkb:recreational_drug
gptkb:Hallucinogen
gptkb:alkaloid
serotonergic psychedelic
entheogen
|
|
gptkbp:chemicalFormula
|
C12H16N2
|
|
gptkbp:color
|
white to yellow crystalline solid
|
|
gptkbp:component
|
gptkb:ayahuasca
|
|
gptkbp:discoveredBy
|
gptkb:Richard_Helmuth_Fredrick_Manske
|
|
gptkbp:discoveredIn
|
1931
|
|
gptkbp:duration_of_effects
|
2-6 hours (oral with MAOI)
5-30 minutes (smoked)
|
|
gptkbp:effect
|
mystical experiences
hallucinations
altered perception of time
|
|
gptkbp:featuredIn
|
book 'DMT: The Spirit Molecule'
|
|
gptkbp:foundIn
|
some animals
various plants
|
|
gptkbp:hasStreet
|
gptkb:Dimitri
the spirit molecule
|
|
gptkbp:IUPACName
|
2-(1H-indol-3-yl)-N,N-dimethylethanamine
|
|
gptkbp:legalStatus
|
gptkb:Schedule_I_(US)
gptkb:Class_A_(UK)
illegal in many countries
|
|
gptkbp:meltingPoint
|
44–46 °C
|
|
gptkbp:metabolism
|
gptkb:monoamine_oxidase
|
|
gptkbp:molecularWeight
|
188.27 g/mol
|
|
gptkbp:notableContributor
|
gptkb:Rick_Strassman
|
|
gptkbp:potential_medical_use
|
studied for PTSD
studied for anxiety
studied for depression
|
|
gptkbp:receptor_affinity
|
5-HT2A receptor agonist
|
|
gptkbp:routeOfAdministration
|
smoked
oral (with MAOI)
vaporized
|
|
gptkbp:solubility
|
slightly soluble in water
soluble in ethanol
|
|
gptkbp:studiedBy
|
psychedelic studies
|
|
gptkbp:used_in
|
traditional South American shamanic practices
|
|
gptkbp:bfsParent
|
gptkb:Psychotria
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dimethyltryptamine (DMT)
|